Robert Driscoll
Stock Analyst at Wedbush
(2.93)
# 1,426
Out of 5,126 analysts
157
Total ratings
37.41%
Success rate
1.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $18 → $19 | $7.75 | +145.16% | 8 | Feb 4, 2026 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $30 → $37 | $31.00 | +19.35% | 9 | Dec 16, 2025 | |
| CGON CG Oncology | Initiates: Outperform | $70 | $50.36 | +39.00% | 1 | Dec 11, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $25 → $34 | $12.23 | +178.00% | 5 | Dec 9, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $7.83 | +385.31% | 11 | Nov 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $80 | $97.49 | -17.94% | 8 | Nov 6, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $31 → $38 | $7.83 | +385.31% | 2 | Oct 20, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $9.52 | +183.61% | 1 | Jul 14, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $2.39 | +67.36% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $0.61 | +880.07% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $19.55 | -13.04% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $57 → $12 | $13.48 | -10.98% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $11.41 | +180.46% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $32.17 | +61.64% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.26 | +609.53% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $21.03 | +42.65% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $7.03 | +1,037.98% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.69 | +1,494.20% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.68 | +128.87% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $12.51 | +3.92% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $13.07 | +466.18% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $6.52 | +22.70% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.53 | +357.52% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $5.67 | +41.09% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.84 | +4.17% | 4 | May 19, 2020 |
Replimune Group
Feb 4, 2026
Maintains: Outperform
Price Target: $18 → $19
Current: $7.75
Upside: +145.16%
Tyra Biosciences
Dec 16, 2025
Maintains: Outperform
Price Target: $30 → $37
Current: $31.00
Upside: +19.35%
CG Oncology
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $50.36
Upside: +39.00%
Cullinan Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $25 → $34
Current: $12.23
Upside: +178.00%
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $7.83
Upside: +385.31%
Revolution Medicines
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $97.49
Upside: -17.94%
Corbus Pharmaceuticals Holdings
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $7.83
Upside: +385.31%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $9.52
Upside: +183.61%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.39
Upside: +67.36%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.61
Upside: +880.07%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $19.55
Upside: -13.04%
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $13.48
Upside: -10.98%
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $11.41
Upside: +180.46%
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $32.17
Upside: +61.64%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.26
Upside: +609.53%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $21.03
Upside: +42.65%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $7.03
Upside: +1,037.98%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.69
Upside: +1,494.20%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.68
Upside: +128.87%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $12.51
Upside: +3.92%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $13.07
Upside: +466.18%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $6.52
Upside: +22.70%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.53
Upside: +357.52%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $5.67
Upside: +41.09%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.84
Upside: +4.17%